Managing Fear of Cancer Progression Metacognition-based Vs Supportive-expressive Based Approaches
Launched by THE UNIVERSITY OF HONG KONG · Dec 23, 2022
Trial Information
Current as of June 28, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at two different ways to help people with advanced cancer who are feeling scared about their illness getting worse. The study will compare two approaches: one called CALM, which focuses on understanding and managing thoughts about cancer, and another called ConquerFear, which provides emotional support and expression. The goal is to see which method works better to reduce fear of cancer progression in Chinese patients.
To participate, you need to be at least 18 years old and speak either Cantonese or Mandarin. You should have recently been diagnosed with advanced or metastatic cancer, which means your cancer is at a later stage. Unfortunately, if you have major difficulties communicating or cannot commit to attending six therapy sessions, you won't be eligible for this study. If you join, expect to take part in these sessions designed to help you cope with your fears in a supportive environment. The trial is currently looking for participants, so it could be a great opportunity to get help while also contributing to important research.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Cantonese- or Mandarin-speaking Chinese patients recently diagnosed with advanced or metastatic (i.e. stage III or IV) cancer
- • are the age of 18 years or above
- Exclusion Criteria:
- • Patients with major communication difficulties
- • are being unwilling or unable to commit 6 psychotherapy sessions
About The University Of Hong Kong
The University of Hong Kong (HKU) is a leading research institution dedicated to advancing medical knowledge and improving healthcare outcomes through innovative clinical trials. With a commitment to excellence in research and education, HKU collaborates with various stakeholders, including healthcare providers and industry partners, to conduct rigorous and ethically sound clinical studies. The university's diverse expertise and state-of-the-art facilities enable it to explore a wide range of therapeutic areas, contributing to the global pursuit of scientific advancement and the development of novel treatment strategies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hong Kong, , Hong Kong
Hong Kong, , Hong Kong
Hong Kong, , Hong Kong
Hong Kong, , Hong Kong
Patients applied
Trial Officials
Wendy Wing Tak Lam, PhD
Principal Investigator
School of Public Health, The University of Hong Kong
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials